MAP2K4(MKK4)
Sign in to save this workspaceUniProt P45985 · PDB · AlphaFold · Substrate: JNK(K55M) · Clone: aa 33-end
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Vemurafenib | 58.0% | 42.0% | 96.49 | 0.598 |
| 2 | Abemaciclib | 47.2% | 52.8% | 91.48 | 0.563 |
| 3 | Defactinib | 38.9% | 61.1% | 92.68 | 0.450 |
| 4 | Gilteritinib | 36.5% | 63.5% | 88.97 | 0.506 |
| 5 | Osimertinib | 35.3% | 64.7% | 97.24 | 0.733 |
| 6 | Pacritinib | 29.0% | 71.0% | 88.64 | 0.452 |
| 7 | Midostaurin | 28.9% | 71.1% | 78.64 | 0.500 |
| 8 | Pazopanib | 22.2% | 77.8% | 97.49 | 0.672 |
| 9 | Ceritinib | 20.5% | 79.5% | 95.44 | 0.618 |
| 10 | Capivasertib | 19.9% | 80.1% | 96.48 | 0.644 |
| 11 | Sunitinib | 18.1% | 81.9% | 91.73 | 0.524 |
| 12 | Dabrafenib | 16.9% | 83.1% | 94.74 | 0.633 |
| 13 | Lazertinib | 16.8% | 83.2% | 97.47 | 0.674 |
| 14 | Rabusertib | 14.3% | 85.7% | 98.74 | 0.687 |
| 15 | Entrectinib | 14.3% | 85.7% | 93.69 | 0.671 |
| 16 | Upadacitinib | 14.0% | 86.0% | 97.98 | 0.663 |
| 17 | Gedatolisib | 13.9% | 86.1% | 99.75 | 0.611 |
| 18 | Ruxolitinib | 13.6% | 86.4% | 98.25 | 0.592 |
| 19 | Lorlatinib | 13.4% | 86.6% | 97.24 | 0.694 |
| 20 | Palbociclib | 12.8% | 87.2% | 98.75 | 0.673 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 3.99
- Epithelial log2(TPM+1): 3.45
- Fold change: 0.55
- Status: No significant change
Selectivity landscape vs inhibition on MAP2K4
Each point is one of the 92 approved drugs; color = inhibition % on MAP2K4.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…